Core Insights - Guardant Health reported a quarterly loss of $0.39 per share, better than the Zacks Consensus Estimate of a loss of $0.48, and improved from a loss of $0.45 per share a year ago, resulting in an earnings surprise of +18.75% [1] - The company achieved revenues of $265.2 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 13.05% and showing a significant increase from $191.48 million in the same quarter last year [2] - Guardant Health's stock has increased by approximately 127.8% since the beginning of the year, outperforming the S&P 500's gain of 17.2% [3] Financial Performance - Over the last four quarters, Guardant Health has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.46 on revenues of $251.41 million, and for the current fiscal year, it is -$1.84 on revenues of $921.37 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Guardant Health belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 grew 39% year-over-year to $265.2 million, marking the first time annualized revenue surpassed $1 billion [6][25] - Non-GAAP gross margin improved to 66% in Q3 2025, up from 63% in the prior year, driven by reduced costs [29] - Adjusted EBITDA loss was $45.5 million, an improvement from a loss of $56.2 million in Q3 2024 [30] Business Line Data and Key Metrics Changes - Oncology revenue increased 31% to $184.4 million, with approximately 74,000 tests performed, reflecting a 40% growth in volume [8][25] - Screening revenue from Shield totaled $24.1 million, generated from 24,000 tests, with an average selling price (ASP) of approximately $880 [28] - Biopharma and data revenue grew 18% year-over-year to $54.7 million, supported by two companion diagnostic approvals [27] Market Data and Key Metrics Changes - The screening business is tracking at an annual run rate of approximately $100 million, one year into the commercial launch of the FDA-approved product [6] - Shield tests have shown high adherence rates, with over 90% of ordered cases resulting in completed blood samples [18] Company Strategy and Development Direction - The company aims to expand its commercial infrastructure for Shield, leveraging partnerships with Quest Diagnostics and Path Group to enhance access [19][20] - Continued investment in commercial initiatives and the introduction of new smart applications are expected to drive future growth [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential inclusion of Shield in American Cancer Society guidelines, which could enhance commercial coverage [40][41] - The company raised its full-year 2025 revenue guidance to $965-$970 million, reflecting stronger-than-expected performance [31][32] Other Important Information - The company surpassed 1 million cumulative clinical patients tested, highlighting the impact of its tests in clinical practice [7] - The submission of the PMA application to the FDA for Guardant360 Liquid is expected to streamline the product offering and enhance market adoption [11] Q&A Session Summary Question: Can you walk us through the Shield ASP dynamics exiting the year? - Management indicated that the ASP for Shield is currently around $1,495, with expectations for continued strong payment from Medicare Advantage [36][37] Question: Is guideline inclusion by the American Cancer Society a real possibility by year-end? - Management remains optimistic about the potential inclusion and its positive impact on reimbursement rates, although it will take time to translate into payments [40][41] Question: How should we think about 2026 growth for Shield? - Management is confident about long-term growth but refrained from providing specific guidance for 2026 at this time [45][46] Question: Can you provide any KPIs around average testing frequency per physician? - Management reported high adherence rates, with over 90% of ordered Shield tests being completed [80]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 grew 39% year-over-year to $265.2 million, marking the first time annualized revenue crossed $1 billion [4][23] - Non-GAAP gross margin improved to 66% in Q3 2025, up from 63% in the prior year, driven by reduced costs [25][26] - Adjusted EBITDA loss was $45.5 million, an improvement of $10.7 million compared to a loss of $56.2 million in Q3 2024 [27] Business Line Data and Key Metrics Changes - Oncology revenue increased 31% to $184.4 million, with approximately 74,000 tests performed, reflecting a 40% growth [23][24] - Screening revenue from Shield totaled $24.1 million, generated from 24,000 tests, with an average selling price (ASP) of approximately $880 [25][16] - Biopharma and data revenue grew 18% to $54.7 million, including milestone revenue from two companion diagnostic approvals [24][14] Market Data and Key Metrics Changes - The company surpassed 1 million cumulative clinical patients tested, indicating strong market penetration [5] - Shield tests demonstrated high adherence rates, with over 90% of ordered cases resulting in completed blood samples [17][76] Company Strategy and Development Direction - The company aims to expand its commercial infrastructure for Shield, enhancing access and awareness through partnerships with Quest Diagnostics and Path Group [19][18] - Continued investment in commercial initiatives and the introduction of new applications through the Infinity AI platform are expected to drive future growth [12][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing demand for Shield and the potential for inclusion in American Cancer Society guidelines, which could enhance commercial coverage [39][38] - The company raised its full-year 2025 revenue guidance to a range of $965 to $970 million, reflecting strong year-to-date performance [28][29] Other Important Information - The company achieved a significant milestone by becoming cash flow positive one quarter earlier than expected, excluding the screening business [5][27] - The introduction of an ultra-sensitive tissue-informed MRD assay is anticipated to complement existing offerings and drive growth [13] Q&A Session Summary Question: Can you walk us through the Shield ASP dynamics exiting the year? - Management indicated that the ASP for Shield is currently around $900, with expectations for stability in Medicare rates at $1,495 for the next two years [32][34] Question: Is guideline inclusion by the American Cancer Society a real possibility by year-end? - Management remains optimistic about potential inclusion but noted that it would take time to translate into reimbursement [37][38] Question: What should we expect for Shield growth in 2026? - Management refrained from providing specific guidance for 2026 but expressed confidence in long-term growth prospects [42][44] Question: Can you discuss the traction for Reveal and its future growth? - Management highlighted that Reveal is the fastest-growing oncology product, with ongoing studies expected to enhance its market position [50][52] Question: What is the timeline for MCD FDA approval based on Shield's trajectory? - Management stated it is too early to provide a specific timeline for FDA approval but remains optimistic about the data being collected [47][48]

Revenue Performance - Revenue for the three months ended September 30, 2025, was $265,196,000, representing a 38.5% increase from $191,476,000 in the same period of 2024[15] - Total revenue for the three months ended September 30, 2025, was $265.2 million, a 38.5% increase from $191.5 million in the same period of 2024[157] - Revenue from the United States was $249.4 million, representing a 38.4% increase compared to $180.1 million in the same period last year[158] - International revenue increased to $15.8 million in Q3 2025, up 38.5% from $11.4 million in Q3 2024[158] - For the nine months ended September 30, 2025, total revenue was $700.8 million, a 30.4% increase from $537.2 million in the same period of 2024[158] Net Loss and Financial Improvement - Net loss for the three months ended September 30, 2025, was $92,725,000, compared to a net loss of $107,754,000 for the same period in 2024, indicating an improvement of 14.5%[15] - The company reported a loss from operations of $98,989,000 for the three months ended September 30, 2025, compared to a loss of $117,328,000 for the same period in 2024, showing a 15.5% improvement[15] - For the nine months ended September 30, 2025, the net loss was $287.8 million, a decrease from a net loss of $325.4 million for the same period in 2024, representing a 11.5% improvement[27] Assets and Liabilities - Total current assets decreased to $828,885,000 as of September 30, 2025, down from $1,055,114,000 as of December 31, 2024, a decline of 21.4%[13] - Total liabilities increased slightly to $1,631,259,000 as of September 30, 2025, compared to $1,625,256,000 as of December 31, 2024[13] - Total stockholders' deficit increased to $354,473,000 as of September 30, 2025, from $139,647,000 as of December 31, 2024[13] - Cash and cash equivalents increased to $580,013,000 as of September 30, 2025, from $525,540,000 as of December 31, 2024, an increase of 10.3%[13] - Total cash, cash equivalents, and restricted cash at the end of September 2025 was $689.5 million, compared to $688.4 million at the end of September 2024, showing a slight increase[27] Research and Development - Research and development expenses for the nine months ended September 30, 2025, were $265,927,000, up from $254,210,000 in the same period of 2024, reflecting a 4.3% increase[15] - Research and development expenses for the three months ended September 30, 2025, were $75.8 million, up from $68.4 million in 2024, reflecting a 6.5% increase[157] Stock-Based Compensation - The company reported stock-based compensation of $123.0 million for the nine months ended September 30, 2025, up from $104.0 million in the same period of 2024, indicating a 18.3% increase[27] - For the three months ended September 30, 2025, total stock-based compensation expense was $42.8 million, a decrease of 14% from $49.8 million in the same period of 2024[140] - Stock-based compensation recorded for performance stock units (PSUs) was $4.9 million for the three months ended September 30, 2025, down from $22.7 million in 2024[138] - Future stock-based compensation for unvested restricted stock units as of September 30, 2025, was $192.8 million, expected to be recognized over 2.0 years[135] Legal and Regulatory Matters - In October 2023, the District Court dismissed with prejudice TwinStrand's infringement claims related to certain patents[119] - The jury awarded TwinStrand Biosciences and the University of Washington $83.4 million in damages, representing a 6% royalty on past sales due to willful patent infringement[120] - The Company filed a patent infringement suit against Tempus AI, Inc., seeking an injunction and compensatory damages for alleged infringement of five patents[121] - The Company was awarded $292.5 million in a lawsuit against Natera for false advertising, including $175.5 million in punitive damages[124] Future Obligations and Commitments - The Company has future principal contractual obligations for operating lease commitments totaling $245.7 million as of September 30, 2025[115] - The weighted-average remaining lease term was 6.9 years as of September 30, 2025[115] Financial Instruments and Debt - The 2027 Notes, with a principal amount of $1.15 billion, will mature on November 15, 2027, and do not bear interest[93] - The 2031 Notes, issued in February 2025, bear interest at a rate of 1.25% per annum and will mature on February 15, 2031[100] - The Company recognized total interest expenses of $943,000 for the three months ended September 30, 2025, and $2.7 million for the nine months ended September 30, 2025[107] - The effective interest rate for the 2031 Notes was 0.4% for the three months ended September 30, 2025[107] Customer and Revenue Concentration - Revenue from significant customers, including Customer B, represented 29% of total revenue for the three months ended September 30, 2025[43] - The Company has not experienced any material losses related to accounts receivable from individual customers or groups of customers[42]

Financial Performance - Total revenue increased to $265.2 million, a 39% increase compared to $191.5 million in Q3 2024 [8, 43] - Oncology revenue grew to $184.4 million, a 31% year-over-year increase from $141.2 million in Q3 2024 [8, 10, 43] - Biopharma & Data revenue reached $54.7 million, an 18% year-over-year increase from $46.5 million in Q3 2024 [8, 28, 43] - Screening revenue was $24.1 million compared to $1.0 million in Q3 2024 [8, 43] - The company is raising revenue guidance for the full year 2025 to $965 million - $970 million, representing approximately 31% year-over-year growth [48] Oncology Business - Oncology volume grew by 40% year-over-year, driven by strong performance across all products [10, 17] - Guardant360 volume growth exceeded 30% year-over-year [17] Screening Business (Shield) - Shield revenue reached $24 million in Q3 2025 [33] - Shield volume increased to 24,000 in Q3 2025 [33] - The company expects 80,000 - 82,000 Shield volume for the full year [48] Biopharma & Data - Two new CDx approvals were obtained in Q3, bringing the total to 23 approvals for Guardant360 CDx [29, 30] Gross Margin - Non-GAAP gross margin increased to 66% in Q3 2025, up from 63% in Q3 2024 [45, 46]

Revenue Performance - Revenue for Q3 2025 was $265.2 million, a 39% increase from $191.5 million in Q3 2024[4] - Total revenue for Q3 2025 reached $265.196 million, a 38.6% increase from $191.476 million in Q3 2024[28] - Oncology revenue grew 31% to $184.4 million, driven by a 40% increase in test volume[4][6] - Oncology revenue for Q3 2025 was $184.402 million, up 30.6% from $141.197 million in Q3 2024[28] - Screening revenue reached $24.1 million, primarily from approximately 24,000 Shield tests[4][6] - Biopharma and Data revenue increased by 18% to $54.7 million, attributed to milestone achievements[4][6] - Biopharma and data revenue increased to $54.731 million in Q3 2025, compared to $46.547 million in Q3 2024, reflecting a growth of 17.5%[28] Profitability and Margins - Gross profit was $171.6 million, with a gross margin of 65%, up from 61% in the prior year[5][6] - Non-GAAP gross margin for Q3 2025 was 66%, compared to 63% in Q3 2024[7][6] - Net loss for Q3 2025 was $92.7 million, an improvement from a net loss of $107.8 million in Q3 2024[9] - GAAP net loss for Q3 2025 was $92.725 million, an improvement from a net loss of $107.754 million in Q3 2024[31] - Non-GAAP net loss per share for Q3 2025 was $0.39, compared to $0.45 in Q3 2024[31] Cash Flow and Financial Position - Free cash flow for Q3 2025 was $(45.8) million, compared to $(55.3) million in the same period last year[11] - Free cash flow for Q3 2025 was $(45.763) million, a decrease from $(55.258) million in Q3 2024[35] - Cash and cash equivalents increased to $580.013 million as of September 30, 2025, up from $525.540 million at the end of 2024[26] - Total assets decreased to $1,276.786 million as of September 30, 2025, down from $1,485.609 million at the end of 2024[26] - Total liabilities slightly increased to $1,631.259 million as of September 30, 2025, compared to $1,625.256 million at the end of 2024[26] - Total stockholders' deficit widened to $(354.473) million as of September 30, 2025, compared to $(139.647) million at the end of 2024[26] Guidance and Future Outlook - The company raised its 2025 revenue guidance to $965 to $970 million, reflecting a year-over-year growth of approximately 31%[1][12] - Operating expenses for Q3 2025 were $270.6 million, up from $234.3 million in the prior year, mainly due to commercial team expansion[8]

Core Insights - Guardant Health and Zephyr AI have formed a strategic partnership aimed at enhancing biopharmaceutical innovation through the integration of multimodal molecular data and AI/ML technology [1] Company Overview - Guardant Health is recognized as a leading precision oncology company, focusing on advanced cancer detection and treatment [1] - Zephyr AI specializes in precision medicine, utilizing artificial intelligence to expedite drug development processes [1] Partnership Details - The collaboration will leverage the unique capabilities of both companies to provide novel, scalable, and actionable insights [1] - The partnership is expected to drive advancements in biopharmaceutical innovation by combining resources and expertise from both organizations [1]

Core Insights - Guardant Health, Inc. is set to present data on the importance of blood-based testing in enhancing cancer screening adherence at the ACG 2025 Annual Meeting [1] Company Overview - Guardant Health is recognized as a leading precision oncology company [1] Event Details - The presentation will take place during the American College of Gastroenterology (ACG) 2025 Annual Meeting in Phoenix, Arizona, from October 24 to October 29, 2025 [1]

Financial Data and Key Metrics Changes - Consolidated revenues for Q3 2025 were $2,820 million, reflecting a 13.1% increase year-over-year, with organic revenue growth of 6.8% [13][16] - Reported operating income was $386 million, or 13.7% of revenues, compared to $330 million, or 13.3% of revenues last year [15][16] - Adjusted EPS for the quarter was $2.60, up from $2.30 a year ago, while reported EPS was $2.16 compared to $1.99 last year [16] - Cash from operations increased to $1,420 million year-to-date, a 63.1% increase from the prior year [17] Business Line Data and Key Metrics Changes - Revenues for Diagnostic Information Services increased by 13.5%, driven by organic growth across physician, hospital, and consumer channels [13] - The physician channel saw approximately 17% revenue growth, with organic growth in the high single digits [4][5] - The hospital channel experienced low single-digit revenue growth, supported by collaborative lab solutions [6] - The consumer channel showed strong double-digit growth, particularly from the questhealth.com platform [7][8] Market Data and Key Metrics Changes - Total volume measured by requisitions increased by 12.5% year-over-year, with organic volume up 3.9% [13][14] - The company noted broad-based demand across clinical solutions, particularly in advanced diagnostics areas such as autoimmune and brain health [4][9] Company Strategy and Development Direction - The company is focused on delivering solutions that meet the evolving needs of core clinical customers and expanding into higher growth areas like consumer health and data analytics [3][4] - Recent acquisitions are emphasized as key growth drivers, particularly in hospital outreach and independent labs [4] - The company is investing in automation and AI to improve operational efficiency and customer experience [11] Management's Comments on Operating Environment and Future Outlook - Management raised the full-year 2025 guidance due to strong performance year-to-date, expecting revenues between $10,960 million and $11,000 million [17][18] - The company is optimistic about potential PAMA reforms, although the passage of the Results Act is uncertain [2][27] - Management expects continued strong demand for clinical solutions and a positive outlook for the consumer health channel [20][36] Other Important Information - The company announced a joint venture with CoreWell Health to establish lab services in Michigan, which is expected to generate approximately $1 billion in annual revenues once fully scaled [7][18] - The company is implementing Project Nova, a multi-year order to cash transformation, with significant investments expected in 2025 [11][18] Q&A Session Summary Question: Utilization backdrop and expectations into year-end - Management noted that raw requisition volume was up 3.9%, with strong growth in autoimmune and advanced cardiometabolic testing, and expects utilization levels to continue into Q4 [22][24][26] Question: Latest expectations on PAMA - Management indicated a likelihood of a PAMA delay, with a potential $100 million impact if PAMA is reinstated, but they can offset some of this impact through controlled investments [27][28] Question: Mix performance relative to expectations - Management stated that consumer channels are performing slightly above expectations, with strong growth in episodic testing and wellness testing [32][34][36] Question: Q4 margins and impacts - Management highlighted strong Q3 margins but noted elevated employee health expenses and increased investments in Project Nova as potential headwinds for Q4 [40][44] Question: Cash flow and one-time benefits - Management confirmed strong cash flow guidance of $1,800 million, noting one-time benefits from the CARES Act and recent tax legislation that may not recur in 2026 [60][62] Question: Consumer health momentum and partnerships - Management discussed partnerships with WHOOP and Aura, highlighting the potential for significant growth in the consumer health segment [68][71] Question: Oncology initiatives and Haystack integration - Management provided updates on the integration of the Haystack MRD test and ongoing studies to expand its indications, with positive market response expected [96][98][112]

Group 1 - The article discusses the mixed performance of major stock indexes, including the Dow Jones Industrial Average, amid concerns over bad loans on Wall Street [1] - Eli Lilly (LLY) and Novo Nordisk (NVO) experienced stock declines following comments from President Donald Trump regarding weight-loss drug pricing [1] - Eli Lilly is focusing on growth and sustainability through a strong drug pipeline, revenue growth, and energy investments [2] Group 2 - The stock market is influenced by fears related to bank stability, with notable declines in stocks such as Oracle and Interactive Brokers [4] - Omeros saw a significant stock increase of 154% due to a surprise $2.1 billion deal with Novo Nordisk [4]